Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Sascha Berger, private biopharmaceutical investor; Shannon Eaker, CTO of Xcellbio; Edwin Stone, CEO of Cellular Origins; and ...

Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the ...

Taylor Fritz blames opponent for Wimbledon curfew controversy after match suspended Senate Republican tax bill passes ‘SALT’ ...

For adults with obesity or overweight, tirzepatide-linked improvements in cardiometabolic risk factors are associated with ...

This change is happening because there’s another covered medication that’s safe and effective for your condition and may cost ...

Protagonist is directly going up against Eli Lilly, which is advancing retatrutide, also a triple-G agonist, in a Phase II ...

While Novo Nordisk stock has underperformed since my Strong Buy rating four months ago, the long-term investment thesis ...

Big Pharmas like Eli Lilly, Sanofi and Novartis headed back to the dealmakers table multiple times, with 32 total deals ...